BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33543377)

  • 1. Is there any place for novel agents in treating biliary tract cancer?
    Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
    Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
    Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
    Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
    J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 6. Second-line therapies in advanced biliary tract cancers.
    Tella SH; Kommalapati A; Borad MJ; Mahipal A
    Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
    Al Mahmasani L; Harding JJ; Abou-Alfa G
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):643-657. PubMed ID: 38423933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum chemotherapy for the management of advanced biliary tract cancer.
    Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
    World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
    Rizzo A
    Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
    [No Abstract]   [Full Text] [Related]  

  • 11. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
    Demols A; Bucalau AM; Mans L
    Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
    Lamarca A; Barriuso J; McNamara MG; Valle JW
    J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment strategies in hepatobiliary cancer.
    Guven DC; Yildirim HC; Chalabiyev E; Kus F; Yilmaz F; Yasar S; Akyildiz A; Aktas BY; Yalcin S; Dizdar O
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):243-256. PubMed ID: 36803258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
    Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
    Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?
    Serrano Uson Junior PL; Bekaii-Saab T
    Immunotherapy; 2023 May; 15(7):531-540. PubMed ID: 37096922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuum of care for advanced biliary tract cancers.
    Vienot A; Neuzillet C
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational development of combination therapies for biliary tract cancers.
    Harding JJ; Khalil DN; Fabris L; Abou-Alfa GK
    J Hepatol; 2023 Jan; 78(1):217-228. PubMed ID: 36150578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.